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Abstract 
Adrenal crises (AC) are life-threatening complications of adrenal insufficiency (AI).  These events 
have an estimated incidence of between 5 and 10 ACs/100 patient years (PY) and are responsible for 
some of the increased morbidity and excess mortality experienced by patients with AI.  Treatment 
involves urgent administration of IV/IM hydrocortisone and IV fluids.  Patient education regarding 
preventive measures, such as increasing the dose of replacement therapy (“stress dosing”) when sick, 
using parenteral hydrocortisone as necessary and accessing medical assistance promptly, is still 
considered the best approach to averting the onset of an AC at times of physiological stress, most 
commonly an infection.  However, recent evidence has demonstrated that patient education does not 
prevent many AC events and the reasons for this are not fully understood.  Furthermore, there is no 
widely accepted definition of AC.  Without a validated AC definition it is difficult to interpret 
variations in the incidence of AC and determine the effectiveness of preventive measures. This article 
aims to review the clinical aspects of AC events; to explore the epidemiology; and to offer a definition 
for an AC and to offer a perspective on future directions for research into AC prevention.   
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Introduction 1 
Adrenal crises (AC) are serious, life threatening complications of adrenal insufficiency (AI).  These 2 
acute episodes constitute one cause of the increased morbidity and mortality in AI [1-6], and account 3 
for a substantial proportion of all AI deaths [1-4,6].   Most ACs occur in the context of exposure to a 4 
physiological stressor, such as an infection or injury, when the concentration of cortisol in the circulation 5 
is insufficient for requirements.  However, knowledge of the physiological processes that contribute to 6 
the development of ACs is incomplete and, furthermore, there is no agreed definition of an AC. 7 
Education is a necessary and important component of AC prevention.  All patients should be 8 
instructed on stress dosing and parenteral glucocorticoid administration; carry a steroid dependency card; 9 
and wear a Medicalert bracelet or similar identification.  Despite these innovations, however, ACs 10 
continue to occur even among patients who have been well educated in preventive strategies [7], and it is 11 
not surprising that they are a major source of anxiety for patients and their families [8].  Frequent reports 12 
of patients having problems accessing appropriate treatment for an AC are highly regrettable and 13 
contribute to the difficulties in preventing ACs in treated AI [9,10].  14 
AC prevention, therefore, continues to be an important conundrum in endocrinology and the 15 
path towards a reduction in the incidence of these events remains uncertain.  The objective of this 16 
paper is to assess the current knowledge regarding ACs; review the definition of an AC in this context; 17 
highlight areas where knowledge is deficient; and suggest topics for further investigation.  In doing so, 18 
we hope to encourage research that can address a number of outstanding issues, with the overall aim 19 
of reducing the incidence of AC events in the future.  20 
 21 
 22 
Incidence and Mortality 23 
 24 
Estimates from a number of well-conducted studies utilizing various designs have demonstrated 25 
that the incidence of AC is between 5 and 10 ACs/100PY in treated AI (Table 1) [7,10-15], with AC 26 
events being somewhat more frequent in primary adrenal insufficiency (PAI) than secondary adrenal 27 
insufficiency (SAI) [2,13,14,16].   The associated mortality rate from AC in treated AI is 0.5/100 PY [7].  28 
However, not all AC related deaths occur in patients who have been diagnosed with AI, and a fatal AC 29 
may be the first diagnosis of AI in some patients [17,18].  Among those with treated AI, AC related 30 
deaths contribute substantially to the increased mortality rate experienced by patients [1-4], being 31 
responsible for up to 15% of all deaths in autoimmune AI [1,4,6,10], and 42% of those in congenital 32 
adrenal hyperplasia (CAH) [2].   Reassuringly though, AC related fatality in hospital is uncommon 33 
(<1%), suggesting that access to timely treatment for an AC is largely successful [19].  Nevertheless, 34 
problems of recognition of an AC as a cause of death are pervasive.  While an AC may be missed as a 35 
cause of death at any age, it is likely that this is more common among older patients who generally have 36 
a greater number of comorbid illnesses, and this may affect mortality estimates.  37 
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Diagnosis and Clinical Considerations  38 
 39 
Although there is no universally accepted definition of an AC, there is general agreement 40 
regarding its underlying pathophysiology and clinical presentation.  Briefly, ACs are acute disturbances 41 
of physiology that happen when the circulating levels of adrenal steroid hormones are insufficient for 42 
physiological requirements.  Haemodynamic compromise, manifest primarily by hypotension, is the 43 
cardinal physiological disturbance of an AC.  Other symptoms and signs include: nausea; vomiting; 44 
abdominal pain; fever; and delirium.  Biochemical abnormalities comprising: hyponatraemia, 45 
hyperkalaemia, hypoglycaemia (usually in children), and hypercalcaemia may also be present [10].    46 
Typically patients with PAI are at higher risk of an AC than those with SAI, as mentioned 47 
earlier.  PAI patients are also considered to be more prone to hyperkalaemia.  This is presumed to be 48 
due to an absence of aldosterone secretion and a complete loss of cortisol production in PAI, while 49 
aldosterone secretion is preserved in SAI and there may also be residual cortisol secretion in some 50 
patients. SAI due to sustained glucocorticoid exposure is common but AC events tend to be rare or 51 
mild, probably reflecting incomplete HPA axis suppression in many treated patients.  For example, 52 
among renal transplant patients taking 5-10 mg prednisolone daily, one-third were found to have 53 
normal ACTH stimulated cortisol levels, indicating lack of suppression and likely low risk of AC 54 
events (20). 55 
An AC is a medical emergency.  Treatment in hospital involves: the urgent administration of 56 
hydrocortisone (100mg IV stat followed by 200mg/24h given as a continuous infusion or frequent IV 57 
(or IM) boluses (50mg) every 6h, with subsequent doses tailored to the clinical response); intravenous 58 
fluids (generally normal saline (1000mL within the first hour, with further crystalloid fluid being 59 
administered according to standard resuscitation guidelines, taking into account the patient’s 60 
circulatory status, body size and relevant comorbidities, and administered with particular caution 61 
among patients with treated diabetes insipidus, as excessive fluids may lead to hyponatraemia)); 62 
treatment of the precipitating cause, if one is evident; and management of any existing comorbidities.  63 
After successful treatment and, in an attempt to prevent further ACs, it is advisable that the patient and 64 
their clinician assess the precipitants of the AC; review any risk factors; reiterate the steps for 65 
prevention; and re-evaluate the patient’s competency in parenteral glucocorticoid administration.   66 
 67 
 68 
Definition 69 
 70 
Despite consensus on the range of clinical features that comprise an AC, problems persist in 71 
both its definition and identification.  There is no universally accepted definition of an AC and the 72 
definitions that are used can differ substantially between clinicians and research studies [10].  This is 73 
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clinically relevant with regards to immediate and longer-term management decisions and is also of 74 
considerable significance to research into AC prevention.   75 
The AC definitions used in research, particularly in studies that involve smaller cohorts and 76 
the assessment of interventions, tend to be project specific and may be detailed in the study report 77 
[7,13,15,21].  By comparison, studies using morbidity and mortality databases [4,16] use diagnoses 78 
that have been coded according to the International Statistical Classification of Diseases and Related 79 
problems (ICD-10-CM), where the rubric E27.2 - “Addisonian or adrenal crisis” (approximate 80 
synonym of severe adrenal insufficiency) [22] denotes the diagnosis of an AC.  However, there is no 81 
detailed guidance given in the ICD-10-CM (or the previous ICD-9-CM) on the symptoms or signs that 82 
define an AC [22] and, as a consequence, the incidence of this code in health-related datasets 83 
represents the interpretation of the various clinical features of acute illness in AI by multiple doctors in 84 
accordance with their own preferred AC definition. 85 
In an attempt to identify a unifying definition of an AC, a number of authors have proposed 86 
new versions, although none to date has been universally accepted [10].  The most recent of these was 87 
included in the 2016 guidelines on PAI management, and mandates the presence of hypotension, 88 
“marked acute abdominal symptoms and marked electrolyte abnormalities” [23].  While electrolyte 89 
abnormalities are required in this particular definition, these are now believed to occur less often in an 90 
AC than was previously thought, possibly resulting in an under-enumeration of true cases of AC and 91 
adversely affecting the utility of this definition in practice [10].  Another definition classifies an AC as “a 92 
major health impairment” and specifies the presence of at least two symptoms or signs, including but not 93 
mandating, electrolyte abnormalities, and requiring the administration of glucocorticoid [7] (Table 2).  A 94 
grading system using levels of hospitalization to denote AC severity was added to this, which assists in 95 
interpretation, but its validity may be affected by variation in the services provided by different 96 
hospitals, particularly with regard to grades 2 and 3 (Table 2) [7].  It may also be confounded by other 97 
factors, such as age and comorbidities, as older patients and those with significant coexisting illnesses 98 
are likely to be admitted to hospital or an intensive care unit at a lower threshold of illness at each level 99 
than healthier younger patients.  100 
By comparison, the two remaining definitions are more general and do not mandate the presence 101 
of specific features (Table 2).  One describes an AC as “a sudden deterioration in a patient with known 102 
AI” [24], while noting in the manuscript that, “the principal manifestation of AC is hypotension or 103 
hypovolaemic shock” [24].  The other defines an AC as “an acute impairment of general health 104 
requiring hospital admission and administration of intravenous saline and glucocorticoids in patients 105 
with AI” [13].  It is noteworthy that this last definition and the one by Hahner et al. (2015) mention 106 
glucocorticoid treatment (but not the resolution of symptoms following its administration) presumably 107 
in an effort to minimize the likelihood of misclassification of other diseases as an AC.  For the same 108 
reason, and in an extension of this idea, Allolio (2015) included a rider on the original definition by 109 
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Hahner et al. (2015), described above, requiring that there be a resolution of symptoms following 110 
administration of intravenous hydrocortisone [10].   111 
Despite these efforts directed towards developing a universal AC definition, none to date has 112 
been accepted and each has strengths and weaknesses.  For this reason, a new definition is proposed in 113 
this review (Table 3).  Like those already described, it follows the general principle of aiming to be clear 114 
and easy to apply, whilst minimising measurement error by reducing false positives (milder 115 
physiological aberrations being classified as an AC, which are prone to occur in definitions that are very 116 
general) and false negatives (actual ACs being classified as milder forms of AI, when the required 117 
features for diagnosis are overly stringent).  Central to considerations around this definition was an 118 
understanding that there is no particular feature of an AC that is diagnostic, and even a set of common 119 
clinical features has limited specificity for the diagnosis.  However, there is general acknowledgement 120 
that haemodynamic disturbance is the central physiological aberration of an AC and, for this reason 121 
hypotension (either absolute or relative) was mandated in this definition (Table 2).   122 
The other new aspect to this definition, like the addition of a demonstrated improvement after 123 
glucocorticoid administration by Allolio (2015) to the original Hahner et al (2015) definition, is that 124 
there needs to be a documented improvement in the patient’s clinical status after the administration of 125 
intravenous hydrocortisone.  However, in this new definition a time frame for the improvement is 126 
included to increase the validity of the AC diagnosis.  This is supported on physiological grounds 127 
because the pressor effects of hydrocortisone on blood pressure in the context of an AC are rapid, 128 
probably reflecting the known effects of hydrocortisone on the peripheral vasculature, which can be 129 
measured in vivo at the macro and microcirculation level (25,26).  The exact time frame of the pressor 130 
response in an AC has not been documented but clinical experience suggests that a response should be 131 
seen within an hour.  Longer periods would indicate that another cause for shock may be present, or 132 
that the AC may have co-occurred with another severe illness, such as septic shock, which would affect 133 
the apparent resolution of the AC.   134 
These extra criteria included in the proposed definition increase the likelihood that true AC 135 
events are identified as such, and that other, less severe episodes of illness, which are nonetheless 136 
important and significant in the context of AI management and surveillance, are not classified as an AC 137 
but rather a milder form of illness, which we suggest can be denoted as “symptomatic AI”.  In addition, a 138 
list of common features of an AC was also included in the present definition to assist in the diagnosis 139 
(Table 2).  Scores from established metrics of illness severity, such as APACHE [27] could also be used 140 
to add information on the seriousness of an AC episode.  141 
 142 
 143 
Risk factors 144 
 145 
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All patients with AI are at risk of an AC in situations, usually of physiological stress, where the 146 
requirement for cortisol is greater than its availability in the circulation.  However, a number of studies 147 
have demonstrated that AC risk is not uniform across all patients and there are some demographic and 148 
personal characteristics of patients that may potentiate this risk [10,16].  As has been mentioned, patients 149 
with PAI appear to be at greater risk of an AC than those with SAI, which may be related to a complete 150 
loss of adrenal function in PAI, or there may be other causes, including complications from endocrine 151 
comorbidities in patients with autoimmune PAI/APS.  For example, thyroid disease is common in 152 
patients with PAI and thyrotoxicosis can precipitate an AC, as can the initiation of thyroid hormone 153 
replacement in a patient with undiagnosed AI [23,28].   Patients with PAI also have an increased 154 
prevalence of type 1 diabetes mellitus, a comorbidity that may be associated with a higher AC risk [16].  155 
Some pharmaceutical agents can also induce AI and, in doing so, increase AC risk [24]. 156 
It is also possible that there may be an association between the glucocorticoid replacement 157 
regimen used by the patient and AC risk.  This may be an issue with the modern approach, which favors 158 
lower doses of shorter-acting glucocorticoids (hydrocortisone and cortisone acetate) in preference to the 159 
longer acting glucocorticoids (prednisolone and dexamethasone) [29].  Although this has not been 160 
identified in follow-up studies and, indeed, glucocorticoid replacement regimen and AC risk may not in 161 
fact be associated, it should be noted that in a recent meta-analysis of the relevant studies, the evidence 162 
base for this negative finding was considered to be weak [30, 30a].  Another possible reason for this 163 
apparent lack of association is that patients who experience an AC event(s) may have their 164 
glucocorticoid dose escalated or altered to prednisolone, potentially masking any association between 165 
low dose glucocorticoid replacement and AC incidence.  Newer formulations, such the dual 166 
(Plenadren®, Duocort®) or delayed release (Chronocort®) forms of hydrocortisone, have not been 167 
examined in terms of AC risk explicitly but to date no specific safety issues have emerged [31].  168 
Age and significant comorbidities may also act as risk factors for the development of an AC in 169 
patients with AI, although the mechanism for this is less clear and may be specific to the individual 170 
comorbidity [16,19].  Other factors that may increase a patient’s predisposition to an AC include 171 
psychological and cognitive difficulties, and social isolation, as these may impair the patient’s ability to 172 
manage their AI, especially the use of stress dosing and parenteral hydrocortisone.  Non-compliance 173 
with treatment is particularly hazardous in AI, and failure to take glucocorticoid replacement according 174 
to instructions places a patient at increased AC risk.   175 
There are also other, as yet unknown, factors that appear to potentiate the AC risk in some 176 
patients [10].  As has been mentioned, it is recognized that there is a subgroup of patients that has a 177 
tendency to develop ACs and can experience multiple episodes.  In contrast, other patients can be 178 
observed for many years without an AC event, despite being at risk of an AC due to underlying AI.  The 179 
reasons for these differences in individual susceptibility to AC are not yet understood and this is an 180 
important area of weakness in the current knowledge, as delineation of this predisposition could facilitate 181 
a considerable reduction in the total number of ACs occurring in a population.  There is also a subgroup 182 
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of AI patients who have persistently reduced well-being despite optimal replacement therapy and it is 183 
possible that the unknown physiological factors which cause this phenomenon may be related to AC 184 
risk, and this warrants further investigation. 185 
 186 
Precipitating factors 187 
 188 
An AC event can be precipitated by a number of factors, most commonly a physiological 189 
stressor, such as an infection or injury.  Indeed, infections are regarded as the most common 190 
precipitants of an AC [7,10,11,19,24] and these can be both bacterial [13,19] and viral (especially in 191 
children) [32].  An infection is a particularly potent AC precipitant because immunomodulation is 192 
partly controlled by cortisol and, in an environment of insufficient circulating cortisol, excess pro-193 
inflammatory cytokines in the circulation can lead to the development of uncontrolled inflammation, 194 
vasodilatation, impaired cardiac function, and shock [25,33].  These effects are amplified by the 195 
absence of the facilitating role of cortisol on catecholamine action on the cardiovascular system (34).  196 
Gastroenteritis is particularly hazardous in AI because vomiting and diarrhoea impair the 197 
adequate absorption of glucocorticoids and also cause dehydration [10,24].  Emotional stress has been 198 
cited as an AC precipitant but the underlying reasons for the association between psychological stress 199 
and an AC are unknown and warrant further investigation.  An abrupt discontinuation of 200 
glucocorticoid therapy may also precipitate an AC, with or without a stressor.  In addition, a 201 
proportion of ACs, perhaps as many as 10%, has no identifiable precipitant [10]. 202 
 203 
 204 
Prevention – is it possible? 205 
 206 
Clinically, the general approach to AC prevention involves a sequence of logical steps, 207 
including: the administration of oral or parenteral glucocorticoids in increased doses when there is an 208 
acute illness; the provision of glucocorticoid cover for surgical procedures, with doses varying 209 
according to illness severity; avoidance of sudden withdrawal of glucocorticoid pharmacotherapy; the 210 
use of a steroid card to inform practitioners of the glucocorticoid requirement for unwell patients [35]; 211 
and the use of a MedicAlert bracelet or similar to identify the patient as having AI when they are 212 
unable to communicate.  213 
Much of the success of AC prevention, however, relies on a patient’s ability to take action to 214 
avert the onset of an AC by recognizing an indicator of physiological stress, such as an infection, and 215 
implementing stress dosing and/or self-administering parenteral glucocorticoids, where appropriate.  216 
However, intensive patient education, which has long been considered the cornerstone of preventive 217 
endeavors, does not appear to be sufficiently effective to enable many patients to take these steps 218 
independently [10].  Indeed intensive education was not found to be more effective than routine 219 
instruction in reducing the incidence of ACs in a recent trial [10].  Unsurprisingly, anxiety about ACs is 220 
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common [8] and may have a number of consequences including unnecessary attendance for medical care 221 
when self-management at home is likely to be effective or inaction or delayed action in the face of a 222 
significant and potentially life-threatening episode of illness.  223 
One area of particular concern is the time that elapses between the onset of symptoms and the 224 
initiation of parenteral therapy, a delay that is often due to a patient’s reluctance or an inability to 225 
transfer from oral stress doses to intramuscular injection of hydrocortisone, particularly in situations 226 
where there are symptoms of vomiting and diarrhea, which impair the absorption of oral 227 
glucocorticoids.  Subcutaneous administration of hydrocortisone may address this problem, as this route 228 
is more acceptable to patients than the intramuscular approach, and its use can be considered preferable 229 
to a situation in which no parenteral hydrocortisone is given [10,36,37].  Recent research demonstrated 230 
that while cortisol levels of greater than 1000 mmol/l from subcutaneous injection were reached more 231 
slowly than through intramuscular injection, this was within an acceptable time limit among patients 232 
with a BMI of less than 27 who were not in shock [36].  Another alternative in this situation may be 233 
rectal hydrocortisone suppositories, providing there is no diarrhea [23,37].  Emergency self-care could be 234 
improved by the introduction of a preloaded hydrocortisone syringe, which obviates the need for an 235 
unwell patient to draw up and then inject hydrocortisone [10].  Unfortunately, this product is not 236 
available and there are no current prospects for its introduction [10]. 237 
Other barriers to successful AC prevention relate to problems with health care delivery, 238 
including inadequate levels of knowledge about AI/AC among clinicians [8,38,39].  Ignorance about 239 
the importance of an AC as a medical emergency can result in patients communicating the need for 240 
urgent treatment to hospital staff, only to be ignored or have the treatment refused, some with severe 241 
consequences [9,10].  The ability of emergency service personnel to administer parenteral 242 
glucocorticoids also varies between jurisdictions and delays may occur in the response to calls for 243 
assistance by emergency services.   Inadequate responsiveness of triaging systems in hospitals and poor 244 
timeliness in the initiation of definitive treatment can also influence the outcome of acute illness in AI 245 
patients [40].  246 
 247 
 248 
 249 
Future directions 250 
 251 
There are many issues that remain unresolved in the pursuit of AC event reduction and targeted 252 
research may help in making progress towards this goal.  Importantly, a number of aspects of AC 253 
physiology are not yet understood and a suite of specifically designed research projects should assist in 254 
improving the knowledge base.  Among these is the need for a more thorough elucidation of the 255 
physiological response to infection.  It is thought that inflammatory cytokine induced HPA axis 256 
activation occurs in combination with rapid cleavage of corticosteroid binding globulin (CBG) by 257 
tissue elastases to enhance cortisol delivery to inflamed tissues [41].  CBG cleavage is an early feature 258 
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of this [42], and the cleavage is associated with increased cortisol secretion and reduced CBG 259 
production.  Consequent depletion of circulating CBG may contribute to inadequate cortisol supply to 260 
inflamed tissues, resulting in heightened tissue damage, as cellular processes become overwhelmed by 261 
unfettered NfΚB activation [41].  However, the relative importance of these processes to the onset of 262 
an AC has not been evaluated and research to determine the range of cytokine/CBG/circulating 263 
hydrocortisone and catecholamine levels at the time of AC presentation, along with relevant 264 
inflammatory markers is needed.   265 
Cortisol is also involved in catalyzing the conversion of adrenomedullary noradrenaline to 266 
adrenaline via the phenylethanolamine N-methyltransferase enzyme, the levels of which are known to 267 
be low in AI (43).  An adequate cortisol level is also required for adrenomedullary organogenesis and, 268 
as a result, the loss of this conversion of noradrenaline to adrenaline may be more pronounced in 269 
congenital forms of AI, such as CAH [44,45].  It is possible that insufficient concentrations of 270 
circulating adrenaline may contribute to the tendency to vascular collapse in AI.  However, the relative 271 
contribution of both adrenaline and noradrenaline to the onset and progression of an AC is unknown 272 
and should be the subject of further research.  273 
It is also not known whether an AC event occurs in the context of a complete deficiency of 274 
circulating glucocorticoid or a relative deficiency, where the level of circulating glucocorticoid is lower 275 
than the concentration that is required for the degree of physiological stress imposed by an illness.  There 276 
have not been studies conducted to examine this issue, largely because of the temporal disconnect 277 
between the determination of serum levels of glucocorticoids and their tissue action.  However, this is of 278 
considerable importance and warrants further examination.   279 
Another area that is worthy of further exploration is the interrelationship between AI and 280 
glucose metabolism.  It has been shown that morning glucose levels are lower in AI patients [45-47], 281 
and recent evidence has demonstrated that occult nocturnal hypoglycaemia can occur in adults with AI 282 
[48,49].   The underlying mechanism for this is likely to involve reduced nocturnal gluconeogenesis 283 
during an overnight fast, a process that is partially dependent on glucocorticoids.  However, 284 
sympathoneural responses may become impaired in AI patients with recurrent nocturnal 285 
hypoglycaemia and this may increase the predilection to, or severity of, AC events.  For this reason, it 286 
would be valuable to assess the frequency of hypoglycaemic events in patients who experience 287 
frequent ACs, as one important element of an investigation into the reasons underlying some patients’ 288 
apparent predisposition to ACs.   289 
In an extension of this idea, a comprehensive investigation into the variability in the apparent 290 
propensity to AC between patients may uncover other factors that influence the risk of AC, such as a 291 
vulnerability to hypoglycaemia, mentioned earlier, and this may be of potential benefit to all patients.  292 
The underlying risk factors, precipitants and responses to stressors among patients who have repeated 293 
episodes of AC should be assessed relative to those in a comparator group who do not have frequent 294 
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ACs, so that any physiological, management, personal or psychological factors that may act to increase 295 
the AC risk can be identified. 296 
A number of epidemiological aspects of AC also require further research and it is important 297 
that, where possible, any methodological limitations of the studies are addressed. Generally, studies on 298 
AC are either cohort studies of small patient groups or population-based studies linking records from 299 
registers or other databases.  Typically, cohort studies conducted on samples of patients offer the 300 
detailed information on treatment and risk factors but may be affected by selection bias, as the study 301 
subjects are often drawn from specialized clinics, offering lower levels of generalizability than well-302 
conducted population based studies [7,14,15].  Surveys of unselected patients, on the other hand, 303 
including those that use convenience samples of patients recruited from AI support groups have lower 304 
levels of validity and usually are affected by selection bias [8,21,50].  Measurement error is also likely to 305 
be present in any study that relies on patient self-report of an AC, although independent record review 306 
may help to minimize the misclassification of AI/AC that is inherent in this approach [15].  307 
By comparison, population-based disease registers can be linked with other databases, such as 308 
hospital admission and mortality records, to provide estimations of AC incidence and mortality [1,2,4].  309 
Alternatively, morbidity databases can be examined to detect changes in incidence that may not be 310 
apparent in a clinical setting, although these sources of information tend to contain fewer clinical details 311 
and may have lower levels of reliability for key data items than well-maintained registers [21,51].   312 
Ongoing monitoring of AC events using these data is important for the prevention of ACs, and is 313 
particularly relevant given that changes in AI management, such as the transition from higher to lower 314 
doses of glucocorticoid replacement therapy, can be initiated without the benefit of a randomized trial.  315 
Changes in incidence are more likely to be identified earlier through ongoing surveillance than in an 316 
individual clinic setting.   317 
Trends in incidence can be assessed and age and sex specific rates or statistical modeling may be 318 
used to determine whether a change is widespread in a patient population or is concentrated in a 319 
subgroup(s) of patients.   Such analyses of population-based data have recently uncovered a number of 320 
new patterns in AC/AI incidence.  A recent Australian study found an increase in hospital admissions for 321 
AC between 2000 and 2012 and another on the same dataset identified geographic variations in AC 322 
incidence [29,51].  Another study in Germany, reported higher AC incidence rates in patients with the 323 
autoimmune polyendocrine syndrome (APS)/PAI [16], and a separate analysis in the same population 324 
noted an increase in the incidence of PAI in women [52].  A further study on Australian patients found 325 
a previously undetected increase in hospital admissions for AC during an interruption to the supply of 326 
20-mg hydrocortisone tablets [53].    327 
This new information illustrates the valuable contribution made by the analysis of incidence data 328 
towards the understanding of the epidemiology of AC but it is noteworthy to remember that the value of 329 
such analyses may be diminished by inconsistencies in the definition of AC.  Coding errors or the 330 
intentional upgrading of codes to reflect greater disease severity may be a potential limitation of 331 
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morbidity data, although the extent to which this affects individual datasets is unknown.   It is also 332 
possible that the use of new indices may assist in a more thorough determination of trends in the severity 333 
of admissions for AC and AI.  These may include use of an AC/AI ratio as a way of assisting in the 334 
interpretation of changes in presentation while controlling for possible fluctuations in baseline disease 335 
rates.  336 
Monitoring mortality rates is also an essential component in the drive to improve health 337 
outcomes in AI and disease registers or linked morbidity and mortality databases can be used for this 338 
purpose [1-4].  However, there is still much that is unknown about the processes that cause death from an 339 
AC, and detailed investigations aimed at determining whether patients suffering an AC were 340 
misdiagnosed and, therefore, not treated for an AC, or whether there were unrecognized complications 341 
due to comorbidities, may assist in reducing the burden of mortality from AC in treated AI.   342 
 343 
 344 
Conclusion 345 
 346 
Despite considerable efforts to reduce the health burden of ACs, these events continue to cause 347 
morbidity and mortality, and are source of considerable anxiety for patients and their families.  Research 348 
studies have increased our understanding of the elements of an AC but many important aspects remain 349 
unresolved.  As a consequence, progress towards a reduction in the occurrence of ACs is at best 350 
incremental and often disappointing.  Outstanding issues variously relate to AC physiology, uncertain 351 
and inconsistent AC definitions applied by multiple clinicians in different settings, and apparent failures 352 
to pursue rigorous investigation of variations in predisposition to AC events in patient sub-groups, 353 
among others.  Available education strategies are logical and certainly useful in preventing or aborting 354 
episodes but the apparent failure of education strategies to change the incidence of AC in treated AI 355 
highlights the necessity for new ideas and approaches to AC prevention. The use of self-administered 356 
subcutaneous parenteral hydrocortisone holds promise but strong confirmatory evidence for its benefit in 357 
situations of incipient AC is lacking.  Development of a preloaded syringe, comparable to the Epipen®, 358 
which can be used to administer the dose of hydrocortisone may be useful but appears to have 359 
insufficient support from industry or government for its introduction.   360 
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